Trials / Approved For Marketing
Approved For MarketingNCT04377152
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
Expanded Access: 68Gallium-PSMA-11 for PET Imaging of Prostate Cancer
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This expanded access protocol provides eligible participants with investigational 68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent treatment strategy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Gallium-PSMA-11 | PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). |
| PROCEDURE | Positron Emission Tomography (PET) | A PET scan is an imaging test that helps reveal how your tissues and organs are functioning using a radioactive drug (tracer) to show this activity |
Timeline
- First posted
- 2020-05-07
- Last updated
- 2021-03-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04377152. Inclusion in this directory is not an endorsement.